Edwards Lifesciences
Edwards Lifesciences Corporation (NYSE: EW) is the leading global structural heart innovation company dedicated to improving patient lives through breakthrough cardiovascular technologies. The company operates through three primary product segments: Transcatheter Aortic Valve Replacement (TAVR), which represented 74%… From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Edwards Lifesciences does
In the company’s own words
Edwards Lifesciences Corporation (NYSE: EW) is the leading global structural heart innovation company dedicated to improving patient lives through breakthrough cardiovascular technologies. The company operates through three primary product segments: Transcatheter Aortic Valve Replacement (TAVR), which represented 74% of net sales in 2025; Transcatheter Mitral and Tricuspid Therapies (TMTT), representing 9% of net sales; and Surgical Structural Heart, representing 17% of net sales. Edwards develops both surgical and transcatheter therapies for aortic, mitral, tricuspid, and pulmonic heart valve diseases, offering patients a comprehensive portfolio of repair and replacement technologies.
The company's flagship TAVR products include the SAPIEN family of valves, which have been implanted in approximately 1.2 million patients worldwide since commercialization began in Europe in 2007 and in the United States in 2011. The TMTT portfolio comprises the PASCAL transcatheter repair system, EVOQUE tricuspid valve replacement system, and SAPIEN M3 mitral valve replacement system. In surgical therapies, Edwards markets the INSPIRIS RESILIA aortic valve and MITRIS RESILIA mitral valve, both featuring proprietary RESILIA tissue technology.
Edwards operates manufacturing facilities across multiple geographies including the United States, Singapore, Costa Rica, and Ireland to ensure continuity of care globally. The company maintains approximately 16,000 employees worldwide, with significant operations concentrated in the United States, Singapore, and Costa Rica. In 2025, 58% of net sales were derived from the United States market, while 42% came from international operations, with Europe representing 60% of international sales, Japan 14%, and Rest of World 26%.
The company sells its products in approximately 100 countries through a combination of direct sales forces and independent distributors. Edwards invests substantially in research and development, allocating approximately 18% of 2025 sales to innovation efforts, with particular focus on transcatheter structural heart programs and clinical evidence generation. Founded over six decades ago by Miles "Lowell" Edwards, the company remains committed to its strategy of transformative product innovation supported by world-class clinical evidence and comprehensive patient support systems. More information is available at www.edwards.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Medical Instruments
- Headquarters
- IRVINE, CA
- Fiscal year end
- December
- CIK
- 1099800
- SIC
- 3842
Financial performance, year by year
Fiscal 2013–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Edwards Lifesciences — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Edwards Lifesciences’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Edwards Lifesciences’s bonds, as funds hold them
Funds report holding 1 issues of Edwards Lifesciences’s debt, $138.06M at market value — what funds hold, not the company’s total debt. Weighted-average coupon 4.30%, maturing 2028 to 2028.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Edwards Lifesciences and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Edwards Lifesciences's earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Edwards Lifesciences's last four quarterly filings that the numbers alone won't show?”